VivoSim Labs, Inc. Costs and Expenses
VivoSim Labs, Inc. (VIVS) reported Costs and Expenses of $2.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-12
- VivoSim Labs, Inc. costs and expenses for the quarter ending 2026-06-30 was $2.78M, a 5.93% decline year-over-year.
- VivoSim Labs, Inc. costs and expenses for the quarter ending 2026-03-31 was $3.23M, a 0.69% increase year-over-year.
- VivoSim Labs, Inc. costs and expenses for the quarter ending 2025-12-31 was $2.78M, a 20.50% decline year-over-year.
- VivoSim Labs, Inc. costs and expenses for the quarter ending 2025-09-30 was $2.66M, a 0.95% increase year-over-year.
- VivoSim Labs, Inc. costs and expenses for fiscal 2026 was $11.62M, a 8.95% decline from fiscal 2025.
- VivoSim Labs, Inc. costs and expenses for fiscal 2025 was $12.76M, a 16.03% decline from fiscal 2024.
- VivoSim Labs, Inc. costs and expenses for fiscal 2024 was $15.20M, a 16.05% decline from fiscal 2023.
- VivoSim Labs, Inc. costs and expenses for fiscal 2023 was $18.10M, a 39.46% increase from fiscal 2022.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.78M 10-Q · filed 2026-08-12 | $6.00M derived: sum of 2 quarters · filed 2026-08-12 | $8.78M derived: sum of 3 quarters · filed 2026-08-12 | $11.44M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $6.00M derived: sum of 2 quarters · filed 2026-07-14 | $8.67M derived: sum of 3 quarters · filed 2026-07-14 | $11.62M 10-K · filed 2026-07-14 |
| 2025-12-31 | $2.78M 10-Q · filed 2026-02-11 | $5.44M derived: sum of 2 quarters · filed 2026-02-11 | $8.39M 10-Q · filed 2026-02-11 | $11.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $2.66M 10-Q · filed 2025-11-06 | $5.62M 10-Q · filed 2025-11-06 | $8.82M derived: sum of 3 quarters · filed 2026-08-12 | $12.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.95M 10-Q · filed 2026-08-12 | $6.16M derived: sum of 2 quarters · filed 2026-08-12 | $9.65M derived: sum of 3 quarters · filed 2026-08-12 | $12.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $6.70M derived: sum of 2 quarters · filed 2026-07-14 | $9.34M derived: sum of 3 quarters · filed 2026-07-14 | $12.76M 10-K · filed 2026-07-14 |
| 2024-12-31 | $3.49M 10-Q · filed 2026-02-11 | $6.13M derived: sum of 2 quarters · filed 2026-02-11 | $9.55M 10-Q · filed 2026-02-11 | $12.68M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $2.64M 10-Q · filed 2025-11-06 | $6.06M 10-Q · filed 2025-11-06 | $9.19M derived: sum of 3 quarters · filed 2025-11-06 | $12.87M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.42M 10-Q · filed 2025-08-12 | $6.55M derived: sum of 2 quarters · filed 2025-08-12 | $10.23M derived: sum of 3 quarters · filed 2025-08-12 | $14.35M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-05 | $6.81M derived: sum of 2 quarters · filed 2025-06-05 | $10.93M derived: sum of 3 quarters · filed 2025-06-05 | $15.20M 10-K · filed 2025-06-05 |
| 2023-12-31 | $3.69M 10-Q · filed 2025-02-19 | $7.80M derived: sum of 2 quarters · filed 2025-02-19 | $12.07M 10-Q · filed 2025-02-19 | $20.01M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-09-30 | $4.12M 10-Q · filed 2024-11-08 | $8.38M 10-Q · filed 2024-11-08 | $16.33M derived: sum of 3 quarters · filed 2024-11-08 | $19.82M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $4.27M 10-Q · filed 2024-08-05 | $12.21M derived: sum of 2 quarters · filed 2024-08-05 | $15.70M derived: sum of 3 quarters · filed 2024-08-05 | $19.13M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $7.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-31 | $11.43M derived: sum of 2 quarters · filed 2024-05-31 | $14.86M derived: sum of 3 quarters · filed 2024-05-31 | $18.10M 10-K · filed 2024-05-31 |
| 2022-12-31 | $3.49M 10-Q · filed 2024-02-08 | $6.92M derived: sum of 2 quarters · filed 2024-02-08 | $10.16M 10-Q · filed 2024-02-08 | |
| 2022-09-30 | $3.43M 10-Q · filed 2023-11-09 | $6.67M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $3.24M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $12.98M 10-K · filed 2023-07-14 | |||
| 2021-06-30 | $2.56M 10-Q · filed 2021-08-06 | $5.16M derived: sum of 2 quarters · filed 2022-06-10 | $7.65M derived: sum of 3 quarters · filed 2022-06-10 | $16.60M derived: sum of 4 quarters · filed 2022-06-10 |
| 2021-03-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-10 | $5.09M derived: sum of 2 quarters · filed 2022-06-10 | $14.04M derived: sum of 3 quarters · filed 2022-06-10 | $16.83M 10-K · filed 2022-06-10 |
| 2020-12-31 | $2.49M 10-Q · filed 2021-02-08 | $11.44M derived: sum of 2 quarters · filed 2021-02-08 | $14.23M 10-Q · filed 2021-02-08 | $17.12M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-09-30 | $8.95M 10-Q · filed 2020-11-05 | $11.74M 10-Q · filed 2020-11-05 | $14.63M derived: sum of 3 quarters · filed 2021-08-06 | $20.16M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-06-30 | $2.79M 10-Q · filed 2021-08-06 | $5.68M derived: sum of 2 quarters · filed 2021-08-06 | $11.21M derived: sum of 3 quarters · filed 2021-08-06 | $19.27M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-15 | $8.43M derived: sum of 2 quarters · filed 2021-06-15 | $16.48M derived: sum of 3 quarters · filed 2021-06-15 | $23.67M 10-K · filed 2021-06-15 |
| 2019-12-31 | $5.53M 10-Q · filed 2021-02-08 | $13.59M derived: sum of 2 quarters · filed 2021-02-08 | $20.78M 10-Q · filed 2021-02-08 | $28.62M derived: sum of 4 quarters · filed 2021-02-08 |
| 2019-09-30 | $8.06M 10-Q · filed 2020-11-05 | $15.25M 10-Q · filed 2020-11-05 | $23.09M derived: sum of 3 quarters · filed 2020-11-05 | $30.39M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $7.19M 10-Q · filed 2020-08-10 | $15.03M derived: sum of 2 quarters · filed 2020-08-10 | $22.34M derived: sum of 3 quarters · filed 2020-08-10 | $29.29M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $7.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-28 | $15.15M derived: sum of 2 quarters · filed 2020-05-28 | $22.10M derived: sum of 3 quarters · filed 2020-05-28 | $30.36M 10-K · filed 2020-05-28 |
| 2018-12-31 | $7.30M 10-Q · filed 2020-02-10 | $14.26M derived: sum of 2 quarters · filed 2020-02-10 | $22.52M 10-Q · filed 2020-02-10 | $31.21M derived: sum of 4 quarters · filed 2020-02-10 |
| 2018-09-30 | $6.95M 10-Q · filed 2019-11-07 | $15.22M 10-Q · filed 2019-11-07 | $23.91M derived: sum of 3 quarters · filed 2019-11-07 | $32.97M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $8.27M 10-Q · filed 2019-08-08 | $16.95M derived: sum of 2 quarters · filed 2019-08-08 | $26.02M derived: sum of 3 quarters · filed 2019-08-08 | $36.95M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-03 | $17.75M derived: sum of 2 quarters · filed 2019-06-03 | $28.68M derived: sum of 3 quarters · filed 2019-06-03 | $39.87M 10-K · filed 2019-06-03 |
| 2017-12-31 | $9.06M 10-Q · filed 2019-02-07 | $20.00M derived: sum of 2 quarters · filed 2019-02-07 | $31.19M 10-Q · filed 2019-02-07 | $42.69M derived: sum of 4 quarters · filed 2019-02-07 |
| 2017-09-30 | $10.93M 10-Q · filed 2018-11-08 | $22.12M 10-Q · filed 2018-11-08 | $33.62M derived: sum of 3 quarters · filed 2018-11-08 | $44.41M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | $11.19M 10-Q · filed 2018-08-09 | $22.69M derived: sum of 2 quarters · filed 2018-08-09 | $33.47M derived: sum of 3 quarters · filed 2018-08-09 | $44.33M derived: sum of 4 quarters · filed 2018-08-09 |
| 2017-03-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | $22.28M derived: sum of 2 quarters · filed 2018-05-31 | $33.14M derived: sum of 3 quarters · filed 2018-05-31 | $42.80M 10-K · filed 2018-05-31 |
| 2016-12-31 | $10.78M 10-Q · filed 2018-02-08 | $21.64M derived: sum of 2 quarters · filed 2018-02-08 | $31.30M 10-Q · filed 2018-02-08 | $40.28M derived: sum of 4 quarters · filed 2018-05-31 |
| 2016-09-30 | $10.86M 10-Q · filed 2017-11-09 | $20.52M 10-Q · filed 2017-11-09 | $29.50M derived: sum of 3 quarters · filed 2018-05-31 | $40.30M derived: sum of 4 quarters · filed 2018-05-31 |
| 2016-06-30 | $9.67M 10-Q · filed 2017-08-09 | $18.65M derived: sum of 2 quarters · filed 2018-05-31 | $29.45M derived: sum of 3 quarters · filed 2018-05-31 | $41.03M derived: sum of 4 quarters · filed 2018-05-31 |
| 2016-03-31 | $8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-05-31 | $19.78M derived: sum of 2 quarters · filed 2018-05-31 | $31.36M derived: sum of 3 quarters · filed 2018-05-31 | $40.13M 10-K · filed 2018-05-31 |
| 2015-12-31 | $10.80M 10-Q · filed 2017-02-09 | $22.38M derived: sum of 2 quarters · filed 2017-02-09 | $31.15M 10-Q · filed 2017-02-09 | |
| 2015-09-30 | $11.59M 10-Q · filed 2016-11-03 | $20.35M 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $8.76M 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $30.87M 10-K · filed 2017-06-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |